Summary
In this phase-3 efficacy trial of a tetravalent dengue vaccine in five Latin American countries, 20,869 healthy children between the ages of 9 and 16 years were randomly assigned in a 2:1 ratio to receive three injections of recombinant, live attenuated, tetravalent dengue vaccine (CYD-TDV) or placebo at months 0, 6, and 12 under blinded conditions, and followed for 25 months. The primary outcome was vaccine efficacy against symptomatic, virologically-confirmed dengue occurring more than 28 days after the third injection. At baseline, 79.4% of an immunogenicity subgroup of 1944 children had seropositive status for one or more dengue serotypes. In the per-protocol population, there were 176 dengue cases (with 11,793 person-years at risk) in the vaccine group and 221 dengue cases (with 5,809 person-years at risk) in the control group, for a vaccine efficacy of 60.8% (95% CI 52.0%, 68.0%). Serotype-specific vaccine efficacy was 50.3% for serotype 1, 42.3% for serotype 2, 74.0% for serotype 3 and 77.7% for serotype 4. Among the severe confirmed dengue cases, 1 of 12 was in the vaccine group, for an intention-to-treat vaccine efficacy of 95.5%. Vaccine efficacy against hospitalization for dengue was 80.3%. The authors concluded that CYD-TDV dengue vaccine was efficacious against virologically-confirmed dengue infection, including severe disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Shepard DS, Halasa YA, Tyagi BK, Adhish SV, Nandan D, Karthiga KS, et al. Economic and disease burden of dengue illness in India. Am J Trop Med Hyg. 2014; 91:1235–42.
Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372:113–23.
Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384:1358–65.
Gupta E, Ballani N. Current perspectives on the spread of dengue in India. Infect Drug Resist. 2014;7:337–42.
Mishra G, Jain A, Prakash O, Prakash S, Kumar R, Garg RK, et al. Molecular characterization of dengue viruses circulating during 2009-2012 in Uttar Pradesh, India. J Med Virol. 2015;87:68–75.
Bedi SK, Prasad A, Mathur K, Bhatnagar S. Positive selection and evolution of dengue type-3 virus in the Indian subcontinent. J Vector Borne Dis. 2013;50:188–96.
Vinodkumar CS, Kalapannavar NK, Basavarajappa KG, Sanjay D, Gowli C, Nadig NG, et al. Episode of coexisting infections with multiple dengue virus serotypes in central Karnataka, India. J Infect Public Health. 2013;6:302–6.
References
Usme-Ciro JA, Méndez JA, Laiton KD, Páez A. The relevance of dengue virus genotypes surveillance at country level before vaccine approval. Hum Vaccine Immunother. 2014;10:2674–8.
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496:504–7.
Smith AW, Macary P. Dengue: Challenges for policy makers and vaccine developers. Curr Infect Dis Rep. 2014;16:404.
References
Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observermasked, placebo-controlled trial. Lancet. 2014;384: 1358–65.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mathew, J.L., Aggarwal, A. & Balasubramanian, S. Tetravalent dengue vaccine for children. Indian Pediatr 52, 237–240 (2015). https://doi.org/10.1007/s13312-015-0614-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-015-0614-1